GABAvsZinc

GABA binds to GABA-A receptors (ligand-gated Cl- channels with alpha1-6, beta1-3, gamma1-3 subunits) and GABA-B receptors (G-protein coupled, Gi/o mediated), reducing neuronal excitability through hyperpolarization. However, supplemental GABA has limited blood-brain barrier penetration due to absence of a dedicated transporter and rapid metabolism by GABA-transaminase and succinate semialdehyde dehydrogenase in periphery. The calming effects may be mediated through: (1) GABA-A and GABA-B receptors in the enteric nervous system (gut-brain axis) — vagal afferents project to the nucleus tractus solitarius and influence limbic regions; (2) small amounts crossing the BBB via paracellular leakage or in individuals with compromised barrier integrity; (3) peripheral effects reducing systemic stress markers (cortisol, heart rate variability). PharmaGABA (Lactobacillus fermentation product) may have better absorption via peptide-like transport or different pharmacokinetics.

Zinc is released from synaptic vesicles (via ZnT3 transporter) during neurotransmission from glutamatergic mossy fiber and Schaffer collateral terminals. It modulates NMDA receptors — at high concentrations zinc blocks the channel at a distinct site from Mg2+, while at low concentrations it potentiates via the GluN2A subunit. Zinc modulates GABA-A receptors (positive allosteric at alpha1, negative at alpha2/3) and glycine receptors. It is required for BDNF synthesis (zinc finger transcription factors) and TrkB signaling. Zinc-dependent enzymes include carbonic anhydrase (CAII, pH regulation), Cu/Zn superoxide dismutase (SOD1, antioxidant defense), and matrix metalloproteinases (synaptic remodeling). In the hippocampus, zinc modulates long-term potentiation (LTP) via CaMKII and MAPK/ERK pathways — the cellular basis of memory formation. Zinc also regulates presynaptic vesicle release.